Keith Speights has positions in Bristol Myers Squibb, Pfizer, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Bristol Myers Squibb, Pfizer, Regeneron Pharmaceuticals ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective increased by Bank of America from $555.00 to $567.00 in a research note issued on Monday,Benzinga reports.

In October 2024, Tom Holland, who has played Spider-Man in six Marvel films, confirmed that the movie would be filming in the summer of 2025. “Next summer, we start shooting,” he shared during ...

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

research-stage immunoprotective approaches - BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily ...

The music video for the song features Hanks recreating scenes from his father Tom Hanks’s 1994 Oscar-winning film “Forrest Gump.” And if that was enough old schoolness, the younger Hanks ...

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

Of those 11, the company believed to have the lowest potential exposure to tariffs is Vertex Pharmaceuticals (NASDAQ: VRTX), since all of its manufacturing occurs within the United States ...

Tom Norton is Newsweek's Fact Check reporter, based in London. His focus is reporting on misinformation and misleading information in U.S. public life. He has in-depth knowledge of open source ...